
Lumos Pharma, Inc. Common Stock
LUMO
LUMO: Lumos Pharma Inc is a biopharmaceutical company that develops treatments for cancer and rare diseases. It carries out both clinical-stage and preclinical research on a range of molecules that help the immune system fight off cancer cells. The treatments are available orally and can be used in conjunction with other cancer therapies. The company also researches an Ebola vaccine. Lumos contracts with manufacturing organizations to make their treatments, engages in partnerships with pharmaceutical companies, and operates primarily in the United States.
moreShow LUMO Financials
Recent trades of LUMO by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by LUMO's directors and management
Government lobbying spending instances
New patents grants
-
Patent Title: Salts and prodrugs of 1-methyl-d-tryptophan Nov. 01, 2022
-
Patent Title: Detecting and treating growth hormone deficiency Feb. 01, 2022
-
Patent Title: Detecting and treating growth hormone deficiency Jan. 26, 2021
-
Patent Title: Synthesis of cyclocreatine and analogs thereof Dec. 03, 2019
-
Patent Title: Synthesis of cyclocreatine and analogs thereof Aug. 13, 2019
-
Patent Title: Detecting and treating growth hormone deficiency Oct. 23, 2018
-
Patent Title: Synthesis of cyclocreatine and analogs thereof Sep. 25, 2018
Federal grants, loans, and purchases
Followers on LUMO's company Twitter account
Number of mentions of LUMO in WallStreetBets Daily Discussion
Recent insights relating to LUMO
Recent picks made for LUMO stock on CNBC
ETFs with the largest estimated holdings in LUMO
Flights by private jets registered to LUMO